Town & Country Bank & Trust CO dba First Bankers Trust CO Reduces Stock Position in Danaher Co. (NYSE:DHR)

Town & Country Bank & Trust CO dba First Bankers Trust CO lessened its stake in shares of Danaher Co. (NYSE:DHR) by 12.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,807 shares of the conglomerate’s stock after selling 1,399 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Danaher were worth $2,727,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Tsfg LLC increased its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the 2nd quarter worth about $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth about $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher in the 1st quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC purchased a new stake in Danaher in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Danaher stock opened at $267.99 on Thursday. The stock’s 50 day moving average price is $270.53 and its 200 day moving average price is $259.65. The firm has a market capitalization of $198.50 billion, a PE ratio of 45.42, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Ratings Changes

Several analysts have commented on DHR shares. The Goldman Sachs Group lifted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners lifted their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Finally, Evercore ISI lifted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.